XRAY SVP granted stock options and RSU awards

DENTSPLY SIRONA Inc. senior vice president Robert Anthony Johnson reported equity awards that increase his direct ownership stake.

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. senior vice president Robert Anthony Johnson reported equity awards that increase his direct ownership stake. On March 4, 2026, he was granted stock options for 202,700 rights to buy shares and an award of 44,643 shares of common stock.

The common stock award consists entirely of restricted stock units that vest in one-third annual installments over three years, ending March 4, 2029

Insider Trade Summary

Grant/Award: 247,343 shares

Grant/Award 2 txns

Insider Johnson Robert Anthony

Role SVP, Chief Supply Chain Office

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	202,700	$0.00	$0.00
Grant/Award	Common Stock	44,643	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 202,700 contracts (Direct); Common Stock — 161,819.146 shares (Direct)

Footnotes (2)

1. F1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.
2. F2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did XRAY executive Robert Anthony Johnson report on this Form 4?

Robert Anthony Johnson reported equity awards, not open-market trades. He received stock options for 202,700 rights to buy shares and a grant of 44,643 shares of common stock, both awarded on March 4, 2026 as part of his compensation.

How do the new restricted stock units for XRAY’s Robert Anthony Johnson vest?

The common stock award consists entirely of restricted stock units that vest in annual one-third installments over three years. Vesting runs through March 4, 2029, meaning one-third becomes available each year if the vesting conditions are met.

What are the key terms of the stock options granted to XRAY executive Robert Anthony Johnson?

Johnson’s 202,700 stock options vest in annual one-third installments over three years, ending March 4, 2029. The exercise price is set at 110% of the closing price of DENTSPLY SIRONA common stock on the grant date, aligning value with future performance.

Did Robert Anthony Johnson buy or sell XRAY shares in the market in this Form 4?

No, the Form 4 reflects grant or award acquisitions rather than market trades. The reported transactions are compensation-related stock options and restricted stock units, both priced at $0.0000 per share in the filing, not open-market purchases or sales.

How many XRAY shares does Robert Anthony Johnson hold after the latest common stock award?

After the 44,643-share common stock grant on March 4, 2026, Johnson’s total direct common stock holdings increased to 161,819.146 shares. This figure reflects his position following the reported award-based acquisition, according to the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Robert Anthony

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28222

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Supply Chain Office

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		44,643(1)	A	$0	161,819.146	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.78	03/04/2026		A		202,700		03/04/2027(2)	03/04/2036	Common Stock	202,700	$0	202,700	D

Explanation of Responses:

1. Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.

2. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.

	/s/ Jessica Nielsen Causey, Attorney-In-Fact for Robert Anthony Johnson	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.